Karen Keenan[1] | Maureen Heddle[1] | Barry Morris[1] | Gary J Macfarlane[1] | Gareth T Jones[1] |
On behalf of BSRBR-AS and BSR-PsA investigators
[1] Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, UK.

British Society for Rheumatology
Ankylosing Spondylitis Register

British Society for Rheumatology
Psoriatic Arthritis Register

Key finding

We operate the AxSpa and PsA Registers for the British Society for Rheumatology with data about quality of life, work and drug safety from over 4400 participants

	BSRBR-AS (closed)		BSR-PsA (recruitment ongoing)	
Population	Adults with Axial Spondyloarthritis		Adults with Psoriatic Arthritis	
Participants	2793	Data collection complete	1700	Correct to end of July 2024
Recruiting centres	85		80	
Recruitment period	2012-2017		From 2018	
Disease classification	Either: And:	• Modified New York (AS) • ASAS criteria (axSpA) • Biologics naïve	Both:	• Clinical diagnosis of PsA • CASPAR classification criteria
Therapy	Either:	• Commencing TNF inhibition • Remaining on conventional therapy	Either: Or:	• Commencing b/tsDMARD having never previously had that agent • Remaining biologics naïve

BSRBR-AS



BSR-PsA



Key findings

- Although patients commencing TNF inhibition in the 'real-world' are similar to patients in clinical trials, they are less likely to respond to treatment (51% vs 62%)
- Early identification of patients at risk of poor work outcome
  - Importance of non-pharmacological therapy and/or targeted occupational support



Progress



- Early analysis supports axSpA findings, re occupational outcomes
- Both registers will contribute to international multi-registry collaborations

EUROSPA